MARKET

ATHX

ATHX

Athersys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.010
-0.160
-7.37%
After Hours: 2.040 +0.03 +1.49% 19:59 03/02 EST
OPEN
2.160
PREV CLOSE
2.170
HIGH
2.170
LOW
2.010
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
4.380
52 WEEK LOW
1.130
MARKET CAP
397.38M
P/E (TTM)
-5.4413
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Athersys to Host Year-End 2020 Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, March 25, 2021, and will...
BusinessWire - BZX · 20h ago
Tissue Regeneration Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Heraldkeepers · 5d ago
Stem Cell & Regenerative Medicine Industry 2016 Global Market Size, Trends, Growth by Top Key Players, Demand and 2024 Forecast
Feb 22, 2021 (AmericaNewsHour) -- The latest market report published by Research Nester "Global Stem Cell & Regenerative Medicine Market...
AmericaNewsHour · 02/22 07:52
Regenerative Medicine Market Size, Share and Analysis to Amass Significant Gains During 2020-2025
Feb 17, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report Regenerative Medicine Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 02/17 10:10
8-K: ATHERSYS, INC / NEW
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 23:11
Athersys Signs Cooperation Agreement With Healios for Cell Therapy Development in Japan
MT Newswires · 02/16 14:25
BRIEF-Athersys Announces Cooperation Agreement With HEALIOS K.K.
reuters.com · 02/16 14:02
Athersys Announces Cooperation Agreement With HEALIOS K.K. To 'reaffirm the mutual commitment to collaborative development of MultiStem in Japan'; Dr. Kagimoto To Dismiss Section 220 Litigation
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. ("Healios"), the
Benzinga · 02/16 12:52
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHX stock price target is 6.80 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 59.67M
% Owned: 30.18%
Shares Outstanding: 197.70M
TypeInstitutionsShares
Increased
43
3.69M
New
30
-10.66K
Decreased
37
5.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Director
Ismail Kola
President/Chief Executive Officer/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Senior Vice President - Finance
Laura Campbell
Senior Vice President
Maia Hansen
Director
Hardy Kagimoto
Director
Katherine Kalin
Director
Baiju Shah
Director
Jane Wasman
Independent Director
Lorin Randall
Independent Director
Kenneth Traub
Independent Director
Jack Wyszomierski
  • Dividends
  • Splits
  • Insider Activity
No Data
About ATHX
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.